Ujvira Injection (160mg), which contains Trastuzumab, is a targeted therapy primarily used in the treatment of certain types of breast cancer and gastric cancer that overexpress the HER2 protein. This medication is designed to inhibit the growth of cancer cells by binding to the HER2 receptor, thereby blocking the signals that promote tumor growth. Ujvira is administered via injection, typically in a clinical setting, and is often part of a comprehensive treatment plan that may include chemotherapy or other therapies. The composition of Ujvira Injection includes Trastuzumab as the active ingredient, which is a monoclonal antibody specifically engineered to target and neutralize HER2-positive cancer cells. This innovative approach to cancer treatment has significantly improved outcomes for patients diagnosed with HER2-positive malignancies, making Ujvira a vital component in modern oncology.